New drug cocktail aims to make inoperable kidney tumors removable

NCT ID NCT06794229

Recruiting now Disease control Sponsor: Qian Qin Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of two drugs, zanzalintinib and nivolumab, given before surgery to people with advanced kidney cancer that is hard to remove. The goal is to shrink the tumor enough so that surgery becomes possible. About 69 participants will receive the drugs for 12 weeks, and if the tumor shrinks, they may proceed to surgery or continue the drugs for up to 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanzalintinib (XL092) and nivolumab (Opdivo)
What this could lead to: If successful, this combination could shrink advanced kidney tumors enough to allow surgery, potentially improving long-term control of the disease.
What could go wrong: This is a small, early-phase trial with no placebo group. The treatment may not work for everyone, and side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED RENAL CELL CARCINOMA

Contacts and locations

Locations

University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
Virginia Commonwealth University
RECRUITING

Richmond, Virginia, 23298, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.